Latest News and Press Releases

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced the launch of...

Ce paiement d’étape renforce la position de trésorerie d’Innate INTERLINK-1 est la première étude de Phase 3 étudiant une approche d’immunothérapie chez des patients présentant un cancer de la tête...

Milestone payment further bolsters Innate’s cash position  INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...

Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...

Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation,...

MARSEILLE, France, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...

Innate a repris le recrutement de patients dans l’essai de Phase 2 TELLOMAK évaluant lacutamab dans le syndrome de Sézary et le mycosis fongoïdesL’entrée en Phase 3 de monalizumab est attendue au...

Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoidesMonalizumab Phase 3 study expected to initiate in the second half of 2020,...

Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoidesMonalizumab Phase 3 study expected to initiate in the second half of 2020,...